Bartholomew J R, Salgia R, Bell W R
Department of Medicine, Johns Hopkins University School of Medicine and Hospital, Baltimore, Md. 21205-2101.
Arch Intern Med. 1989 Sep;149(9):1959-61.
Patients with thrombocytopenia have an increased risk of bleeding. We have used 18 courses of aminocaproic acid in 17 patients with either immune or nonimmune thrombocytopenia to successfully control hemorrhage associated with reduced platelet counts. The types of hemorrhage controlled included the following: vaginal, gastrointestinal, intracerebral, cutaneous, mucous membrane, subconjunctival, and renal, as well as that associated with dental extractions, tracheostomy, and sites of Penrose drains. The number of platelet and red blood cell transfusions administered decreased substantially following institution of aminocaproic acid therapy. We conclude that therapy with aminocaproic acid is safe and useful in the management of bleeding in patients with both immune and nonimmune thrombocytopenia.
血小板减少症患者出血风险增加。我们对17例免疫性或非免疫性血小板减少症患者使用了18疗程的氨基己酸，成功控制了与血小板计数降低相关的出血。所控制的出血类型包括：阴道出血、胃肠道出血、脑出血、皮肤出血、黏膜出血、结膜下出血和肾出血，以及与拔牙、气管切开术和橡皮引流管部位相关的出血。在使用氨基己酸治疗后，输注的血小板和红细胞数量大幅减少。我们得出结论，氨基己酸治疗在免疫性和非免疫性血小板减少症患者的出血管理中是安全且有用的。
